Q-omics provides the consensus-scored OR2I1P profile across patient tissues and cancer cell-line models. OR2I1P expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, OR2I1P is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, OR2I1P RNA expression shows 17,648 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where OR2I1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2I1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2I1P survival associations across molecular data types. OR2I1P RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2I1P RNA expression–survival associations across cancer types. High OR2I1P expression shows unfavorable associations in UVM and KIRP, but favorable associations in SKCM, HNSC, OV and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for OR2I1P RNA expression.
This table summarizes OR2I1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR2I1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2I1P shows higher tumor expression in KIRC, COAD, LIHC, STAD, HNSC and BRCA. The KIRC box plot shows higher OR2I1P RNA expression in tumor versus normal tissue (log2 FC = +3.483, t-test p < 0.001).
This table shows molecular features associated with OR2I1P in patient tissues and cancer cell lines. In patient samples, OR2I1P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
